Fentanyl decreases clearance of midazolam administered i.v., but the mechanism remains unclear. To elucidate this mechanism, we have investigated the effect of fentanyl on metabolism of midazolam using human hepatic microsomes and recombinant cytochrome P450 isoforms 
Midazolam is a widely used i.v. anaesthetic. It is metabolized by hepatic microsomal cytochrome P4503A (CYP3A) and its clearance is dependent on CYP3A activity. [1] [2] [3] [4] Some drugs, such as antimycotics, macrolide antibiotics and calcium channel blocking agents reduce the clearance of midazolam by inhibiting CYP3A activity, resulting in prolonged drowsiness and inhibition of psychomotor performance. [5] [6] [7] In clinical practice, midazolam is often used in combination with opioids, and clearance of midazolam is reduced by simultaneously administered fentanyl. 8 As fentanyl is also metabolized by CYP3A, 9 competitive inhibition of CYP3A by fentanyl may be responsible for the reduced clearance of midazolam. Although metabolism of midazolam has been studied extensively in vitro and in vivo, [1] [2] [3] [4] no studies have examined the effect of fentanyl on the metabolism of midazolam by cytochrome P450 (P450).
In this study, we have examined the direct inhibitory effects of fentanyl on metabolism of midazolam by CYP3A using human hepatic microsomes and recombinant human hepatic P450 isoforms.
Materials and methods
The study was approved by the Institutional Human Investigational Committee. Midazolam and its metabolites, © British Journal of Anaesthesia 1Ј-hydroxymidazolam (1Ј-OH MDZ), 4Ј-hydroxymidazolam (4Ј-OH MDZ) and 1Ј,4Ј-hydroxymidazolam (1Ј,4Ј-OH MDZ) were gifts from Hoffmann-La Roche Ltd (Nutley, USA). Fentanyl was purchased from Sankyo Pharmaceuticals Co. Ltd (Tokyo, Japan). Sulphaphenazole was a gift from Meiji Yakuhin Co. Ltd (Tokyo, Japan). Troleandomycin, quinidine and diethyldithiocarbamate were obtained from Sigma Chemical Co. (St Louis, MO, USA). Human hepatic microsomes were obtained from the International Institute for the Advancement of Medicine (Scranton, USA). These microsomes were prepared from liver samples of kidney donors by differential centrifugation, and specific contents of P450 were 0.33-0.66 nmol mg protein -1 . Recombinant human P450s, expressed in human lymphoblast cells with cytochrome P450 reductase, were obtained from Gentest (Woburn, USA). These P450s were supplied as microsomes. Reduced nicotinamide adenine dinucleotide phosphate (NADPH) was obtained from the Oriental Yeast Co. (Tokyo, Japan). A C18-column (TSK gel ODS-120T, 4.6ϫ150 mm) was obtained from the Tosoh Corp. (Tokyo, Japan). Other reagents and organic solvents were obtained from Wako Pure Chemical Industries (Osaka, Japan).
Assay of midazolam metabolism
Metabolism of midazolam was measured using the method reported previously, with small modifications. 10 Briefly, midazolam 0.2-10.0 µmol litre -1 was incubated at 37°C for 2 min with hepatic microsomes (100 µg of protein) and NADPH 0.4 mmol litre -1 in potassium phosphate buffer 0.1 mol litre -1 (pH 7.4) in the presence or absence of one of the chemical inhibitors of P450 in a final volume of 500 µl (nϭ6). When metabolism of midazolam was measured using the P450 isoform, CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 or 3A4, 30 pmol of the P450 was used instead of human hepatic microsomes, and the incubation time was 10 min. Concentration of NADPH was saturable and the formation rates of 1Ј-OH MDZ were linear up to 15 and 30 min for the substrate concentrations used with microsomes and P450s, respectively. Concentrations of the P450 chemical inhibitors, sulphaphenazole, quinidine, diethyldithiocarbamate andtroleandomycin were 1, 10, 100 and 100 µmol litre -1 , respectively. Concentrations of these inhibitors were sufficient to suppress more than 80% of CYP2C, 2D, 2E and 3A activities in human hepatic microsomes. 11 In our preliminary study, troleandomycin 100 µmol litre -1 also inhibited formation of 1Ј-OH MDZ by recombinant CYP3A4 by 95%. Concentrations of fentanyl were 0, 15, 30 and 45 µmol litre -1 . The reaction was stopped by adding 50 µl of sodium hydroxide 1 mol litre -1 to the incubation mixture and placing it immediately on ice. Metabolites were extracted and measured by high-performance liquid chromatography (HPLC) as reported previously. 8 The limit of detection of 1Ј-OH MDZ, 4Ј-OH MDZ and 1Ј,4Ј-OH MDZ was 20 nmol litre -1 . Intra-and inter-assay coefficients of variation were less than 4.8% and 7.0%, respectively.
Kinetic analysis of midazolam 1Ј-hydroxylation and inhibition by fentanyl
The maximum rate of metabolism (Vmax) and the Michaelis-Menten constant (K m ) for the formation of 1Ј-OH MDZ from midazolam were determined by linear regression from Lineweaver-Burk double-reciprocal plots. When fentanyl was added to the reaction mixture, the inhibition pattern was determined by visual inspection of double-reciprocal plots for fentanyl concentration vs the velocity of the reaction. The apparent K m for each concentration of fentanyl was estimated by linear regression analysis using unweighted raw data following a simple (one enzyme) Michaelis-Menten kinetic approach. The inhibition constant (K i ) values were determined by unweighted linear regression analysis using the following equation 12 :
where K m ϭaffinity constant in the absence of inhibitor, apparent K m ϭK m in the presence of inhibitor, and Iϭ concentration of inhibitor.
Statistical analysis was performed by one-way analysis of variance for comparison of the formation rates of 1Ј-OH MDZ in the absence or presence of P450 inhibitors. This 
Results

Metabolism of midazolam by human hepatic microsomes
When midazolam was incubated with human hepatic microsomes, 1Ј-OH MDZ was the only metabolite detected on the HPLC profiles. The total amount of residual midazolam and 1Ј-OH MDZ formed in the incubation mixture was approximately equal to the total amount of midazolam added to the reaction, suggesting that 1Ј-OH MDZ was the predominant midazolam metabolite. Of the P450 inhibitors studied, only troleandomycin significantly inhibited 1Ј-OH MDZ (PϽ0.01) while other P450 inhibitors were ineffective. Fentanyl 45 µmol litre -1 significantly inhibited the formation of 1Ј-OH MDZ (PϽ0.05) (Fig. 1) . As troleandomycin is a selective CYP3A inhibitor, these findings suggest that CYP3A is predominantly responsible for 1Ј-OH MDZ, and that fentanyl is a potent CYP3A inhibitor.
When midazolam was incubated with human hepatic microsomes, single-phase straight lines were obtained from the Lineweaver-Burk plots for 1Ј-hydroxylation ( Fig. 2A) . K m was 5.0 (SD 2.7) µmol litre -1 and Vmax was 6.3 (2.1) nmol min -1 mg protein -1 (nϭ6). These values are comparable with those reported previously. 1 2 4 When fentanyl was added to the reaction mixture, metabolism of midazolam was inhibited in a competitive manner, with a K i of 26.8 (12.4) µmol litre -1 (nϭ6) (Fig. 2A) . These findings suggest that a single P450 isoform in human hepatic microsomes was involved in the formation of 1Ј-OH MDZ, and that the metabolic activity of the P450 isoform was inhibited by fentanyl.
Metabolism of midazolam by recombinant human P450
Only CYP3A4 catalysed hydroxylation of midazolam to 1Ј-OH MDZ, suggesting that CYP3A4 is selectively involved in the metabolism in human hepatic microsomes. Formation rates of 1Ј-OH MDZ by CYP3A4 were 0.10 (0.01) and 2.57 (0.13) nmol min -1 nmol P450 -1 with midazolam 0.2 and 10.0 µmol litre -1 , respectively (nϭ6). Inhibition of midazolam metabolism was therefore studied using recombinant CYP3A4.
K m and Vmax for midazolam 1Ј-hydroxylation by recombinant CYP3A4 were 3.6 (0.8) µmol litre -1 and 4.7 (0.9) nmol min -1 nmol P450 -1 , respectively (nϭ6). K m value with CYP3A4 was comparable with that obtained with human hepatic microsomes. Formation of 1Ј-OH MDZ by CYP3A4 was competitively inhibited by fentanyl, with a K i of 24.2 (6.8) µmol litre -1 (nϭ6) (Fig. 2B) . This K i value was also comparable with that obtained in human hepatic microsomes, suggesting that CYP3A4 in human hepatic microsomes was competitively inhibited by fentanyl, and that this inhibition was therefore responsible for the decreased clearance of midazolam in vivo. 8 
Discussion
There are a large number of studies on the metabolism of midazolam. [1] [2] [3] [4] However, only few have elucidated the midazolam metabolic activity of each P450 isoform. 2 3 Our study, using human hepatic microsomes and recombinant P450 isoforms, showed that only CYP3A4 metabolized midazolam, and that other representative P450s in human hepatic microsomes did not.
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CYP3A4 is the most abundant P450 isoform in human hepatic microsomes and is involved in the metabolism of a large number of agents, including fentanyl. 9 13 As one drug may inhibit the metabolism of other drugs when they are metabolized by the same P450, 14 metabolism of midazolam may be inhibited by drugs metabolized by CYP3A4. However, there have been no reports demonstrating direct inhibitory effects of fentanyl on metabolism of midazolam by CYP3A4. In this study, fentanyl inhibited metabolism of midazolam by CYP3A4, and the pattern of inhibition was competitive (Fig. 2) , suggesting that fentanyl binds to the substrate binding site of CYP3A4. Alfentanil is also metabolized selectively by CYP3A4 and produces hypnotic and anaesthetic effects synergistically with midazolam. 15 16 These anaesthetic interactions may also have resulted from decreased clearance of midazolam induced by inhibition of CYP3A4 activity by alfentanil, although pharmacokinetic interactions between midazolam and alfentanil have not been reported.
Multiple P450 isoforms have been detected in the CYP3A family in the liver. 13 CYP3A5, 3A7 and CYP3A4 catalyse midazolam hydroxylation, 2 3 although CYP3A5 and 3A7 were not tested in our study. CYP3A5 is found in only 20-30% of adult human livers, and CYP3A7 is found only in fetal liver, 13 17 suggesting that CYP3A4 is predominantly responsible for metabolism of midazolam in human hepatic microsomes.
In addition to 1Ј-OH MDZ, 4Ј-OH MDZ and 1Ј,4Ј-OH MDZ are formed by P450 from midazolam. [1] [2] [3] However, 4Ј-OH MDZ and 1Ј,4Ј-OH MDZ were not detected in our experiments, consistent with findings reported previously. 4 This probably resulted from the higher K m and lower Vmax values for 4Ј-hydroxylation than for 1Ј-hydroxylation of midazolam. 1 2 In particular, the K m for midazolam 4Ј-hydroxylation is more than 50 µmol litre -1 , approximately 10-fold higher than the K m for 1Ј-hydroxylation. 2 At the concentrations of midazolam tested in this study, the formation rates of 4Ј-OH MDZ and 1Ј,4Ј-OH MDZ would have been too low to be detected. As CYP3A4 is involved in midazolam 4Ј-hydroxylation and 1Ј-hydroxylation, [1] [2] [3] formation of 4Ј-OH MDZ should also be inhibited by fentanyl.
In this study, the K i value for inhibition of midazolam 1Ј-hydroxylation by CYP3A4 was 24.2 (6.8) µmol litre -1 . In contrast, plasma concentrations of fentanyl in clinical practice are usually lower than 1.0 µmol litre -1 . Fentanyl is highly lipophilic, becomes highly concentrated in vascular rich tissues and concentrations of fentanyl in the liver are several fold higher than those in plasma. 18 19 Therefore, the higher K i values obtained in this study compared with concentrations of fentanyl in plasma do not rule out the occurrence of drug-drug interactions in vivo.
In summary, we have demonstrated competitive inhibition of metabolism of midazolam by fentanyl in vitro. Although reduction of hepatic blood flow induced by various conditions such as hypotension and mechanical ventilation may reduce clearance of midazolam in clinical practice, clearance is dependent predominantly on CYP3A4 activity in the liver, 4 and inhibition of CYP3A4 by fentanyl may be responsible for decreased clearance of midazolam when coadministered. 8 Interactions between midazolam and fentanyl produce prolonged hypoxaemia and apnoea. 20 An in vitro study of interactions of anaesthetics using human hepatic microsomes would be useful for predicting possible interactions of anaesthetics in clinical practice.
